Coherus Oncology, Inc.
CHRS
$0.7472
-$0.0204-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.58% | -371.55% | 16.79% | -112.56% | 229.15% |
| Total Depreciation and Amortization | 1.26% | -33.31% | 30.50% | -21.23% | 41.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.76% | 124.58% | 411.73% | 98.00% | -345.74% |
| Change in Net Operating Assets | -80.09% | 188.64% | -182.85% | 752.70% | -278.65% |
| Cash from Operations | -190.28% | 146.13% | -203.82% | 227.73% | -261.49% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -100.00% | -- | -- |
| Other Investing Activities | -3,126.20% | -222.07% | 103.60% | -106.09% | 475.98% |
| Cash from Investing | -3,126.20% | -222.07% | -98.39% | -86.36% | 475.98% |
| Total Debt Issued | -- | 100.00% | -100.38% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -58.00% | 69.14% |
| Repurchase of Common Stock | -2,540.00% | 0.00% | 99.42% | -129.66% | -128.53% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -100.04% | 29,036.00% | 162.81% |
| Cash from Financing | -214.29% | 238.32% | 99.91% | -21,286.58% | 142.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -254.00% | 145.83% | 38.59% | -164.08% | 593.20% |